Figure 2.

Distribution of COMMANDER HF participants and observed stroke or transient ischaemic attack rates by CHA₂DS₂-VASc score. * Given strong treatment effect of rivaroxaban vs. placebo on stroke/transient ischaemic attack, Cox proportional hazards models for risk prediction were performed in the placebo group alone.